1. Platinum nanoparticles (PtNPs)-based CRISPR/Cas12a platform for detection of nucleic acid and protein in clinical samples.
- Author
-
Liang, Jiajie, Teng, Peijun, Hu, Liangshan, He, Guanbo, Song, Qifang, Zhang, Ying, Peng, Bin, Li, Gan, Xiao, Wei, Cao, Donglin, and Tang, Yong
- Subjects
- *
APTAMERS , *SARS-CoV-2 , *PLATINUM nanoparticles , *COVID-19 , *NUCLEIC acids , *CRISPRS - Abstract
Early rapid screening diagnostic assay is essential for the identification, prevention, and evaluation of many contagious or refractory diseases. The optical density transducer created by platinum nanoparticles (PtNPs) (OD-CRISPR) is reported in the present research as a cheap and easy-to-execute CRISPR/Cas12a-based diagnostic platform. The OD-CRISPR uses PtNPs, with ultra-high peroxidase-mimicking activity, to increase the detection sensitivity, thereby enabling the reduction of detection time and cost. The OD-CRISPR can be utilized to identify nucleic acid or protein biomarkers within an incubation time of 30–40min in clinical specimens. In the case of taking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N gene as an instance, when compared to a quantitative reverse transcription-polymerase chain reaction (RT-qPCR), the OD-CRISPR test attains a sensitivity of 79.17% and a specificity of 100%. In terms of detecting prostate-specific antigen (PSA), aptamer-based OD-CRISPR assay achieves the least discoverable concentration of 0.01 ng mL−1. In general, the OD-CRISPR can detect nucleic acid and protein biomarkers, and is a potential strategy for early rapid screening diagnostic tools. [Display omitted] • A noble metal nanocatalysts-based CRISPR/Cas12a assay (OD-CRISPR) is reported. • The OD-CRISPR is used for the detection of nucleic acid in clinical samples. • The aptamer-based OD-CRISPR is used for the detection of protein in clinical samples. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF